Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

By The Northwire Desk — AI Analysis Jan 13, 2026 · 21:00 BCT · 15.22 BRIACELL THERAPEUTICS CORP. J
BCT · Price

Executive Summary

  • BriaCell Therapeutics announced a best‑efforts public offering of 5,366,726 units at $5.59 per unit for gross proceeds of approximately $30 million.
  • Each unit includes one common share (or pre‑funded warrant) and one warrant exercisable at $6.93 per share, expiring five years from issuance; warrants are expected to begin trading on Nasdaq under “BCTXL” on Jan. 14, 2026.
  • Net proceeds will be used for working capital, general corporate purposes, and advancing the Company’s business objectives.

Key Details

  • Units offered: 5,366,726 (each unit = 1 common share or pre‑funded warrant + 1 warrant).
  • Pricing: $5.59 per unit (inclusive of pre‑funded warrant exercise price).
  • Gross proceeds: Approximately $30 million before placement agent fees and offering expenses.
  • Warrant terms: Immediately exercisable; purchase one common share at $6.93 per share; expire five years from issuance.
  • Listing: Warrants approved for Nasdaq Capital Market listing; expected ticker BCTXL on Jan. 14, 2026.
  • Closing date: Anticipated Jan. 15, 2026, subject to customary closing conditions.
  • Placement agent: ThinkEquity (sole placement agent).
  • Regulatory filings: Form S‑1 (File No. 333-292388) effective Jan. 13, 2026; related registration statement filed under Rule 462(b) on the same date.
  • Use of proceeds: Fund working capital, general corporate purposes, and further development of BriaCell’s immunotherapy programs.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other